Skip to main content
×
Home

Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors

  • A. Demjaha (a1), J. M. Lappin (a2), D. Stahl (a3), M. X. Patel (a1), J. H. MacCabe (a1), O. D. Howes (a1) (a4), M. Heslin (a5), U. A. Reininghaus (a1), K. Donoghue (a6), B. Lomas (a1), M. Charalambides (a1), A. Onyejiaka (a1), P. Fearon (a7), P. Jones (a8), G. Doody (a9), C. Morgan (a1) (a10), P. Dazzan (a1) (a2) and R. M. Murray (a1)...
Abstract
Background

We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors.

Method

The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up. We collated clinical information on severity of symptoms, antipsychotic medication and treatment adherence during the follow-up period to determine the presence, course and predictors of treatment resistance.

Results

From the 23% of the patients, who were treatment resistant, 84% were treatment resistant from illness onset. Multivariable regression analysis revealed that diagnosis of schizophrenia, negative symptoms, younger age at onset, and longer duration of untreated psychosis predicted treatment resistance from illness onset.

Conclusions

The striking majority of treatment-resistant patients do not respond to first-line antipsychotic treatment even at time of FEP. Clinicians must be alert to this subgroup of patients and consider clozapine treatment as early as possible during the first presentation of psychosis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
*Address for correspondence: A. Demjaha, Ph.D., Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK. (Email: arsime.demjaha@kcl.ac.uk)
Footnotes
Hide All

Joint first author.

Joint senior author.

Footnotes
References
Hide All
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72, 14391444.
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441449.
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 7193.
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry 75, e11e13.
Demjaha A, Morgan K, Morgan C, Landau S, Dean K, Reichenberg A, Sham P, Fearon P, Hutchinson G, Jones PB, Murray RM, Dazzan P (2009). Combining dimensional and categorical representation of psychosis: the way forward for DSM-V and ICD-11? Psychological Medicine 39, 19431955.
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 169, 12031210.
Dreher JC, Meyer-Lindenberg A, Kohn P, Berman KF (2008). Age-related changes in midbrain dopaminergic regulation of the human reward system. Proceedings of the National Academy of Sciences 105, 1510615111.
Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM (2011). Time to treatment response in first episode schizophrenia: should acute treatment trials last several months? Journal of Clinical Psychiatry 72, 1691.
Gardner DM, Murphy A, O'Donnell H, Centorrino F, Baldessarini RJ (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686693.
Harrell FE Jr. (2015). Regression Modeling Strategies: with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd edn. Springer-Verlag: New York.
Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001). Recovery from psychotic illness: a 15- and 25-year international follow-up study. British Journal of Psychiatry 178, 506517.
Hastie T, Tibshirani R, Friedman J (2009). The Elements of Statistical Learning, 2nd edn. Springer: New York.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU (2016). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry. doi:10.1176/appi.ajp.2016.16050503.
Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789796.
Kolakowska T, Williams A, Ardern M, Reveley M, Jambor K, Gelder M, Mandelbrote B (1985). Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction. British Journal of Psychiatry 146, 229239.
Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, Mondelli V, Marques TR, Pariante C, Dazzan P, Shergil SS, Howes OD, David AS, MacCabe JH, Gaughran F, Murray RM (2016). Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine 46, 32313240.
Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H (2012). Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research 137, 141146.
Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50, 369376.
Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR (1992). Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry 149, 11831188.
MacMillan JF, Crow TJ, Johnson AL, Johnstone EC (1986). Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 148, 128133.
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry 62, 975983.
McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, Watt JA, Greene JG, Kershaw PW, Todd NA (1989). The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatrica Scandinavica 80, 597602.
Meltzer HY (1997). Treatment-resistant schizophrenia – the role of clozapine. Current Medical Research and Opinion 14, 120.
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry 154, 475482.
Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, Doody GA, Dazzan P (2014). Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychological Medicine 44, 27132726.
National Institute for Health and Care Excellence (NICE) (2014). Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). Royal College of Psychiatrists: London.
Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, Cooper SJ (2014). Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. European Neuropsychopharmacology 24, 499509.
Team R Core (2014). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria.
Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 156, 544549.
Schennach R, Riedel M, Musil R, Moller HJ (2012). Treatment response in first-episode schizophrenia. Clinical Psychopharmacology and Neuroscience 10, 7887.
Sheitman B, Lieberman J (1998). The natural history and pathophysiology of treatment resistant schizophrenia. Journal of Psychiatric Research 32, 143150.
Susser E, Finnerty M, Mojtabai R, Yale S, Conover S, Goetz R, Amador X (2000). Reliability of the life chart schedule for assessment of the long-term course of schizophrenia. Schizophrenia Research 42, 6777.
World Health Organization (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva.
World Health Organization (1994). Schedules for Clinical Assessment in Neuropsychiatry Version 2: Manual. World Health Organization, Division of Mental Health: Geneva.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 71
Total number of PDF views: 601 *
Loading metrics...

Abstract views

Total abstract views: 996 *
Loading metrics...

* Views captured on Cambridge Core between 11th April 2017 - 23rd November 2017. This data will be updated every 24 hours.